- Medical cannabis sector will be worth $18-20 billion in the next five years
- Israel to allow medical cannabis exports in the coming months
- BOL Pharma creating next generation of medical cannabis drugs
Jerusalem, May 9, 2017... Dr. Tamir Gedo, CEO of BOL Pharma will speak on obstacles and solutions for developing cannabis drugs that meet FDA approval requirements at the upcoming conference “Practicalities in Cannabis Research and Clinics” to be held in Jerusalem on June 1, 2017 at The International Convection Center (Binunay Ha’Uma).
Safe and effective cannabis based therapies can disrupt the market as more countries and US states legalize medical cannabis. Estimates are that the sector will be worth $18-20 billion in the next five years. In Israel, the world’s capital of medical cannabis research and development, BOL Pharma is taking a pharmaceutical approach to develop unique cannabis based solutions.
Dr. Gedo’s panel will take place at 9:15-10:45 am. Other panelists include Yuval Landschaft, Director of the Israel Medical Cannabis Agency, Ministry of Health, Hagai Hillman, Chairman, BOL Pharma and Liam Gal-On, CEO of Ilan Bio.
About BOL Pharma
BOL Pharma has been pioneering the creation of the medical cannabis industry in Israel since 2008. Working in conjunction with the Israeli Ministry of Health and under governmental licenses, BOL serves thousands of patients, doctors, HMOs, and hospitals providing cannabis based medical products and cannabinoid APIs (active pharmaceutical ingredients) as a full service CDMO for clinical research, pharmaceuticals, food supplements and dermacosmetics.
BOL is engaged in collaborations with universities, academic institutions, and hospitals to develop novel drugs and obtain regulatory approvals in these therapeutic areas:
• Immunology (Multiple Sclerosis, Fibromyalgia)
• Pain Management (Chronic Pain, Neuropathic Pain)
• Gastrointestinal Diseases (IBD)
• Rheumatology (Osteoarthritis)
• Dermatology (Psoriasis, Atopic Dermatitis)
• Neurology (Autism)
For further information or to interview Tamir Gedo contact Laura Kam at laura@kamgs.com.
